Direxion Daily S&P Biotech Bull 3X ETF
LABU
36 hedge funds and large institutions have $56.8M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2024 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 7 closing their positions.
58% more call options, than puts
Call options by funds: $85.3M | Put options by funds: $54M
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
9% more funds holding
Funds holding: 33 → 36 (+3)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
0.41% less ownership
Funds ownership: 5.76% → 5.34% (-0.41%)
19% less capital invested
Capital invested by funds: $70.4M → $56.8M (-$13.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$6.83M |
| 2 |
Goldman Sachs
New York
|
+$5.36M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$5.24M |
| 4 |
GS
GTS Securities
New York
|
+$3.05M |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$18.2M |
| 2 |
JP Morgan Chase
New York
|
-$4M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$2.92M |
| 4 |
Morgan Stanley
New York
|
-$2.36M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.2M |
LABU Hedge Fund Activity: Q2 2024 in Review
36 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q2 2024, worth a combined $56.8M — down 19% from $70.4M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new LABU positions and 7 closed out — a net gain of 4 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $6.83M. The largest seller was Barclays, exiting entirely with an estimated $18.2M sold.
- 36 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q2 2024, up from 33 in Q1 2024.
- Funds reported $56.8M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q2 2024, down 19% quarter-over-quarter.
- 11 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q2 2024 and 7 closed out, a net change of +4 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q2 2024 was HRT Financial, an estimated $6.83M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q2 2024 was Barclays, an estimated $18.2M sold.
Based on aggregated 13F filings for Q2 2024.